Date Published:
2012 Apr 24

Publication Type:
Journal Article

Authors:

D. Croteau
B.M. Best
S. Letendre
S.S. Rossi
R.J. Ellis
D.B. Clifford
A.C. Collier
B.B. Gelman
J.C. McArthur
J.Allen McCutchan
S. Morgello
I. Grant

Secondary:
AIDS

Volume:
26

Pagination:
890-3

Issue:
7

PMID:
22313954

URL:
https://pubmed.ncbi.nlm.nih.gov/22313954

DOI:
10.1097/QAD.0b013e328351f627

Keywords:
Adult;CCR5 Receptor Antagonists;CHARTER;Chromatography, Reverse-Phase;Cross-Sectional Studies;Cyclohexanes;Female;HIV Infections;HIV-1;Humans;Inhibitory Concentration 50;Internal;Male;Maraviroc;Middle Aged;RNA, Viral;Tandem Mass Spectrometry;Triazoles

Abstract:
<p>To measure maraviroc total cerebrospinal fluid (CSF) concentrations and compare them with total and unbound plasma concentrations. Total maraviroc was measured by reverse-phase high-performance liquid chromatography with tandem mass spectrometry, whereas ultrafiltration was used for unbound maraviroc. Maraviroc was detected in all nine CSF/plasma pairs with a median CSF total concentration of 2.4 ng/ml. CSF concentrations exceeded the 50% inhibitory concentration of wild-type CC chemokine receptor 5-tropic HIV-1 in all specimens. CSF concentrations are lower than expected based on plasma concentrations and physicochemical characteristics. Unbound maraviroc plasma concentrations may be informative in estimating concentrations in CSF.</p>